The COVID-19 Patient Confidence Study, a weekly measure of consumer attitudes and behavior, shows that consumer confidence is at the highest levels since the onset of COVID-19.
72% of patients have reported that they are not delaying a doctor visit to discuss a condition. In addition, the majority of patients expect to go to the HCP in the next two months or sooner, while only 37% expected to go in the next two months on April 30.
86% of consumers are comfortable visiting healthcare providers, over twice the confidence of visiting a restaurant or the 36% comfortable attending a public gathering such as a rock concert or sports event.
Physician search has significantly increased across the country from late March. For example, in Nevada, there was an increase of 129%; in Texas, there was an increase of 111%; and in New York an increase of 114%.
The research also shows that telemedicine has played an important role in delivering care. According to the survey, 30% of respondents have participated in telemedicine in the past 3 months and 83% are open to interacting with their care provider virtually.
Infosurv Research is a boutique research agency based in Atlanta, GA.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study